Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 2/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.33 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8628508 | 1.00 | CYP2C9 (0.38) | CYP2C9POLBCTSSCTSKTRPA1 | |
| SCHEMBL10827228 | 0.80 | FAAH (0.56) | ALDH1A1 | |
| SCHEMBL19318580 | 0.79 | POLB (0.41) | POLBCTSSCTSKTRPA1MMP2 | |
| SCHEMBL19318533 | 0.79 | POLB (0.41) | POLBCTSSCTSKTRPA1MMP2 | |
| SCHEMBL2757967 | 0.79 | POLB (0.41) | POLBCTSSCTSKTRPA1MMP3 | |
| SCHEMBL16360269 | 0.79 | CYP2C9 (0.42) | CYP2C9MMP2MMP3ALDH1A1 | |
| SCHEMBL21579982 | 0.77 | PSENEN (0.39) | CYP2C9CTSSCTSK | |
| SCHEMBL13611899 | 0.77 | POLB (0.39) | POLBCTSSCTSKTRPA1 | |
| SCHEMBL10067158 | 0.77 | CYP2C9 (0.41) | CYP2C9CTSSCTSKALDH1A1 | |
| SCHEMBL13758669 | 0.77 | CYP2C9 (0.41) | CYP2C9POLBCTSSCTSKALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291998-A1 | EPONEMYCIN AND EPOXOMICIN ANALOGS AND USES THEREOF | EISAI R&D MANAGEMENT CO., LTD. | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291998-A1 | EPONEMYCIN AND EPOXOMICIN ANALOGS AND USES THEREOF | PSMC4, PSMB6, EPOR | CYP2C9 3222/4885POLB 2096/4885CTSS 1097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.